CL2022002645A1 - Glucagon derivatives with improved stability - Google Patents
Glucagon derivatives with improved stabilityInfo
- Publication number
- CL2022002645A1 CL2022002645A1 CL2022002645A CL2022002645A CL2022002645A1 CL 2022002645 A1 CL2022002645 A1 CL 2022002645A1 CL 2022002645 A CL2022002645 A CL 2022002645A CL 2022002645 A CL2022002645 A CL 2022002645A CL 2022002645 A1 CL2022002645 A1 CL 2022002645A1
- Authority
- CL
- Chile
- Prior art keywords
- glucagon
- present
- improved stability
- hypoglycemia
- prevention
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un nuevo péptido derivado del glucagón y a una composición para la prevención o el tratamiento de hipoglucemia, que contiene el nuevo péptido derivado del glucagón como principio activo. El derivado de glucagón de acuerdo con la presente invención tiene propiedades físicas mejoradas debido al cambio en el punto isoeléctrico (pI) mientras que es capaz de mantener una actividad en los receptores del glucagón y, por tanto, puede mejorar la conformidad del paciente cuando se usa como un agente hipoglucémico y también es adecuado para la administración en combinación con otros agentes antiobesidad. Por consiguiente, el derivado de glucagón de acuerdo con la presente invención se puede usar de manera eficaz para la prevención y el tratamiento de la hipoglucemia y la obesidad.The present invention relates to a new glucagon-derived peptide and to a composition for the prevention or treatment of hypoglycemia, which contains the new glucagon-derived peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being able to maintain an activity at glucagon receptors and thus can improve patient compliance when used. It is used as a hypoglycemic agent and is also suitable for administration in combination with other anti-obesity agents. Therefore, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2022002645A CL2022002645A1 (en) | 2022-09-28 | 2022-09-28 | Glucagon derivatives with improved stability |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2022002645A CL2022002645A1 (en) | 2022-09-28 | 2022-09-28 | Glucagon derivatives with improved stability |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022002645A1 true CL2022002645A1 (en) | 2023-05-26 |
Family
ID=86558113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022002645A CL2022002645A1 (en) | 2022-09-28 | 2022-09-28 | Glucagon derivatives with improved stability |
Country Status (1)
Country | Link |
---|---|
CL (1) | CL2022002645A1 (en) |
-
2022
- 2022-09-28 CL CL2022002645A patent/CL2022002645A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017001718A1 (en) | Glucagon derivatives with improved stability | |
CL2021003419A1 (en) | Glucagon-like peptide-1 receptor agonists | |
AR112480A1 (en) | COMPOSITIONS OF GLP-1 AND ITS USES | |
AR026986A1 (en) | PHARMACEUTICAL IMPLANT WITH CONTENT OF IMMEDIATE RELEASE AND SUSTAINED RELEASE COMPONENTS AND METHODS OF ADMINISTRATION | |
BRPI0704238A (en) | preventive of coccidiosis and clostridial disease and / or therapy for coccidiosis and clostridial disease | |
BR112021002069A2 (en) | Composition for hair treatment, methods and uses. | |
BR112015023071A2 (en) | insulin-incretin conjugates | |
BR112018067896A2 (en) | apparatus for subretinal administration of therapeutic agent through a curved needle | |
NI200800169A (en) | USE OF BENZO-FUSED HETEROCYCLIC SULFAMID DERIVATIVES FOR THE TREATMENT OF PAIN | |
BRPI0513168A (en) | memantine as adjunctive treatment for atypical antipsychotics in patients with schizophrenia | |
ECSP20070185A (en) | NEW GLP-1 ANALOGUES | |
MX2019009922A (en) | Oil based formulations for sublingual and buccal delivery. | |
AR062775A1 (en) | PHARMACEUTICAL COMPOSITION ABLE TO IMPROVE THE ACTIVITY OF LPG -1 IN A HUMAN BEING AND ITS USE TO PREPARE A MEDICINAL PRODUCT | |
BR112018074108A2 (en) | drug delivery syringes and exact dose control mechanisms | |
BR112023018842A2 (en) | SELECTIVE DRUG RELEASE OF CONJUGATES | |
UY38067A (en) | MODIFIED RELAXIN B-CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | |
CL2022002646A1 (en) | Glucagon derivatives with improved stability | |
CL2022002645A1 (en) | Glucagon derivatives with improved stability | |
CL2022002644A1 (en) | Glucagon derivatives with improved stability | |
AR110193A1 (en) | INSULIN ANALOGS OF FAST STABILITY IMPROVED ACTION | |
AR048370A1 (en) | COMPOSITION TO IMPROVE COGNITIVE FUNCTIONS AND MEMORY | |
EA202000347A1 (en) | ANTI-SARS-CoV-2 VIRAL AGENT ANTIPROVIR | |
CL2022000320A1 (en) | Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions | |
EP4338751A3 (en) | Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor | |
CU20200030A7 (en) | PEPTIDE FOR THE TREATMENT OF INFECTIONS CAUSED BY CORONAVIRUS |